Schmid P, Sablin MP, Bergh J, Im SA, et al. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with
exemestane and everolimus in hormone receptor-positive, HER2-negative locally
advanced/metastatic breast cancer. Breast Cancer Res 2021;23:8.
PMID: 33451345